Swiss National Bank raised its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) by 7.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 131,700 shares of the biopharmaceutical company's stock after acquiring an additional 8,900 shares during the quarter. Swiss National Bank owned approximately 0.23% of Vanda Pharmaceuticals worth $1,490,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Qube Research & Technologies Ltd boosted its position in Vanda Pharmaceuticals by 9.0% in the first quarter. Qube Research & Technologies Ltd now owns 88,076 shares of the biopharmaceutical company's stock valued at $996,000 after buying an additional 7,297 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Vanda Pharmaceuticals by 74.8% during the first quarter. Fisher Asset Management LLC now owns 69,588 shares of the biopharmaceutical company's stock valued at $787,000 after purchasing an additional 29,786 shares during the last quarter. Royce & Associates LP grew its stake in shares of Vanda Pharmaceuticals by 99.2% during the first quarter. Royce & Associates LP now owns 239,627 shares of the biopharmaceutical company's stock valued at $2,710,000 after purchasing an additional 119,329 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Vanda Pharmaceuticals by 11.6% in the first quarter. SG Americas Securities LLC now owns 104,944 shares of the biopharmaceutical company's stock valued at $1,187,000 after purchasing an additional 10,919 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in Vanda Pharmaceuticals by 134.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 8,540 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 4,900 shares in the last quarter. Institutional investors own 99.42% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, June 3rd.

Insider Activity at Vanda Pharmaceuticals

Vanda Pharmaceuticals Trading Down 4.0 %

Shares of NASDAQ VNDA opened at $10.38 on Friday. The firm has a market capitalization of $587.10 million, a PE ratio of 54.05 and a beta of 0.47. The firm's 50-day moving average is $10.83 and its 200-day moving average is $10.89. Vanda Pharmaceuticals Inc. has a 1 year low of $9.24 and a 1 year high of $21.44.

Vanda Pharmaceuticals Profile

(Get Rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Featured Stories

• Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
• Could Snap Stock Rebound As Management Restructures?
• MarketBeat: Week in Review 8/29 – 9/2
• Hormel Looks Cheap At These Levels
• Lululemon Set To Soar Into September
• Could Nike Stock be Oversold, but Still Overvalued?

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.